Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | JAK1 | P23458 | 3/20 | 0.38 |
| ▸ | JAK2 | O60674 | 3/20 | 0.38 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | DHODH | Q02127 | 2/20 | 0.35 |
| ▸ | TRPM2 | O94759 | 1/20 | 0.35 |
| ▸ | FPR2 | P25090 | 1/20 | 0.35 |
| ▸ | DDX3X | O00571 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | XDH | P47989 | 1/20 | 0.34 |
| ▸ | TYK2 | P29597 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20551922 | 0.93 | TRPM2 (0.41) | MEN1KMT2AJAK1JAK2MAPT | |
| SCHEMBL21749293 | 0.85 | CACNA1B (0.44) | CYP2C9CYP2C19DHODHTP53 | |
| SCHEMBL20552657 | 0.77 | JAK1 (0.43) | JAK1JAK2MAPTDHODHFPR2 | |
| SCHEMBL21765173 | 0.77 | MAPK14 (0.43) | MAPTDHODHFPR2DDX3X | |
| SCHEMBL25786909 | 0.76 | GAA (0.36) | MEN1KMT2AJAK2MAPTDHODH | |
| SCHEMBL20552661 | 0.75 | BRAF (0.42) | MEN1KMT2AJAK2MAPTDHODH | |
| SCHEMBL20552924 | 0.75 | KMT2A (0.43) | MEN1KMT2ACYP2C9CYP2C19MAPT | |
| SCHEMBL20552438 | 0.74 | SMN1; SMN2 (0.46) | MEN1KMT2AMAPTDHODHTRPM2 | |
| SCHEMBL20551791 | 0.73 | RAB9A (0.45) | MEN1KMT2AMAPTDHODHTRPM2 | |
| SCHEMBL20552417 | 0.73 | MAPT (0.55) | MEN1KMT2AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230192607-A1 | TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF | TEAD1, TEAD4, TEAD2 | MEN1 3125/4885KMT2A 1804/4885JAK1 4685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.